Impact of Nirsevimab on Respiratory Syncytial Virus <scp>PCR</scp> Test Positivity in Young Infants: A Community‐Level Observational Study in Queensland, Australia
We present the first real-world community-based evidence on the impact of nirsevimab upon RSV detection percentages in infants aged ≤ 3 months in Queensland, Australia. The nirsevimab-based prevention program may be contributing to a substantial decline in RSV detection percentages among young infants in the community.
Authors
- Keith Grimwood (ORCID: https://orcid.org/0000-0003-3174-9834)
- Robert S. Ware (ORCID: https://orcid.org/0000-0002-6129-6736)
- Jennifer Robson (ORCID: https://orcid.org/0000-0001-7207-244X)
- Sarah G. Cherian
- Stephen B. Lambert
- Chanpaseuth Vicki Vilaylath
- Asmaa El‐Heneidy
Institutions
- Griffith University (AU)
- The University of Queensland (AU)
- Wesley Research Institute (AU)
- Sullivan Nicolaides Pathology (AU)
Publication Details
- Journal
- Journal of Paediatrics and Child Health
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1111/jpc.70317
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Sanofi
- Griffith University
- Medical Research Council
- National Health and Medical Research Council